ATOS - Atossa Genetics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.7437
+0.1937 (+7.60%)
As of 11:00AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.5500
Open2.5900
Bid2.7300 x 900
Ask2.8000 x 900
Day's Range2.5401 - 2.8275
52 Week Range0.8000 - 7.3900
Volume299,818
Avg. Volume3,140,982
Market Cap25.035M
Beta (3Y Monthly)5.18
PE Ratio (TTM)N/A
EPS (TTM)-4.3670
Earnings DateAug 12, 2019 - Aug 16, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • GlobeNewswire8 days ago

    Atossa Genetics Announces First Quarter 2019 Financial Results and Provides Company Update

    SEATTLE, May 13, 2019 -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast.

  • ACCESSWIRE21 days ago

    "The Digital Economy & World Markets"

    SAN FRANCISCO, CA / ACCESSWIRE / April 30, 2019 / Vista Partners ("Vista") has published April 2019's FREE Macroeconomic & Investment Monthly Newsletter, "The Digital Economy & World Markets." ...

  • GlobeNewswire26 days ago

    Atossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit

    SEATTLE, April 25, 2019 -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer.

  • ACCESSWIRE29 days ago

    Reducing This Amino Acid May Aid In Fight Against Breast Cancer

    SAN FRANCISCO, CA / ACCESSWIRE / April 22, 2019 / According to The American Cancer Society ( ACS ) breast cancer is the most common cancer in American women, except for skin cancers. Currently, the average ...

  • GlobeNewswire29 days ago

    Atossa Genetics to Present at the 4th Annual Precision: Breast Cancer World R&D Summit April 25, 2019

    SEATTLE, April 22, 2019 -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer.

  • GlobeNewswire2 months ago

    Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update

    SEATTLE, March 28, 2019 -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast.

  • ACCESSWIRE2 months ago

    "Bull Market Hopping?"

    SAN FRANCISCO, CA / ACCESSWIRE / March 27, 2019 / Vista Partners ("Vista") has published March 2019's FREE Macroeconomic & Investment Monthly Newsletter, "Bull Market Hopping?" Vista's ...

  • GlobeNewswire2 months ago

    Atossa Genetics Announces Institutional Review Board Approval of Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

    Atossa Genetics Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that the Institutional Review Board (IRB) has approved the use of Atossa’s oral Endoxifen as a post-mastectomy treatment in a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient. "IRB approval was the final step in making our oral Endoxifen available to this patient,” commented Dr. Steven C. Quay, President and CEO of Atossa. “We are encouraged that the regulatory authorities recognize the potential for additional treatment options for pre-menopausal breast cancer patients.

  • GlobeNewswire2 months ago

    Atossa Genetics Announces Receipt of $10 Million

    Atossa Genetics Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that on March 14 and 15, 2019, it received approximately $10 million from exercises of previously outstanding warrants. “The $10 million in cash proceeds significantly enhances our cash position and provides working capital for our ongoing and planned clinical studies,” commented Kyle Guse, CFO and General Counsel of Atossa Genetics.

  • What Type Of Shareholder Owns Atossa Genetics Inc.’s (NASDAQ:ATOS)?
    Simply Wall St.2 months ago

    What Type Of Shareholder Owns Atossa Genetics Inc.’s (NASDAQ:ATOS)?

    Every investor in Atossa Genetics Inc. (NASDAQ:ATOS) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insidersRead More...

  • Atossa Genetics News: FDA Approval Sends ATOS Stock Skyrocketing
    InvestorPlace2 months ago

    Atossa Genetics News: FDA Approval Sends ATOS Stock Skyrocketing

    Atossa Genetics news about it getting approval from the U.S. Food and Drug Administration (FDA) for one its its drugs has its stock soaring.Source: Shutterstock Atossa Genetics (NASDAQ:ATOS) has announced that its breast cancer drug Endoxifen has been given special approval by the FDA. This approval is for using the drug to treat a specific patient under the organization's expanded access program.This Atossa Genetics news has the company using Endoxifen as a "post-mastectomy treatment in a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient." This same patient also took part in a three-week course of the drug prior to her surgery.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Winning High-Yield Dividend Stocks With Payouts Over 5% Here's what Dr. Steven C. Quay, President and CEO of Atossa Genetics, has to say about the news."We are extremely pleased that this patient not only benefitted from Endoxifen prior to her surgery, but that the FDA agrees that continued Endoxifen therapy is appropriate for this pre-menopausal patient. This positive progress supports our expansion of oral Endoxifen clinical trials. After surgery is completed, the current standard of care in the USA to prevent a recurrence and/or a new cancer is for patients to undergo ovarian ablation (chemical treatment to induce menopause) and take aromatase inhibitors (AI) for 5 to 10 years. Alternatively, tamoxifen therapy can be used for 5-10 years for those patients who do not want to take AIs, or for whom these medications are contraindicated. This patient, like many others, was not a good candidate for tamoxifen therapy due to low liver enzyme (CYP2D6) activity which means her liver would not adequately metabolize tamoxifen. Unlike tamoxifen, oral Endoxifen does not require liver metabolism so it may be a better treatment approach."ATO stock was up 249% as of noon Thursday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Stocks Sitting on Huge Piles of Cash * The 10 Best Stocks to Buy for the Bull Market's Anniversary * 7 Dividend Stocks With Big Yields As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Atossa Genetics News: FDA Approval Sends ATOS Stock Skyrocketing appeared first on InvestorPlace.

  • GlobeNewswire2 months ago

    Atossa Genetics Announces FDA Approval of Oral Endoxifen for “Expanded Access” as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

    Atossa Genetics Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that the FDA has issued a “Safe to Proceed” letter under their “expanded access” program permitting the use of Atossa’s oral Endoxifen as a post-mastectomy treatment in a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient. This patient completed a 3-week course of Atossa’s oral Endoxifen prior to her surgery under an FDA-approved expanded access program. The tumor activity from the initial biopsy was compared to the tumor activity at surgery, finding that the cancer cell biological activity was reduced by two measures: the Ki-67 activity decreased by 50 percent, and the estrogen receptor content decreased by over 20 percent.

  • ACCESSWIRE3 months ago

    "On Fed's Wings" Vista Partners Publishes February 2019's Macroeconomic & Investment Monthly Newsletter

    SAN FRANSISCO, CA / ACCESSWIRE / February 27, 2019 / Vista Partners ("Vista") has published February 2019's FREE Macroeconomic & Investment Monthly Newsletter, "On Fed's Wings." Vista's ...

  • GlobeNewswire3 months ago

    Atossa Genetics Reports Results From “Expanded Access” Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability Issues

    SEATTLE, Feb. 07, 2019 (GLOBE NEWSWIRE) -- , February 7, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today updated the status of the pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient who received preoperative oral Endoxifen therapy under an FDA-approved “expanded access” program. The purpose of this therapeutic approach was to reduce activity of the cancer cells prior to surgery. There were no safety or tolerability issues and her surgery was completed successfully.

  • GlobeNewswire3 months ago

    Atossa Genetics Provides Breast Cancer Prevention Recommendations to the United States Preventative Services Task Force

    Atossa Genetics Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has provided suggested changes to the draft recommendation of the United States Preventative Services Task Force (USPSTF) concerning “Breast Cancer: Medications for Risk Reduction.” The public comment period ends February 11, 2019 and the finalized USPSTF recommendations will become available in July 2019. Mammographic breast density (MBD) provides the only patient level, biology-based assessment that is predictive of future breast cancer and it is modifiable.

  • ACCESSWIRE4 months ago

    Vista Partners January 2019 Monthly Macroeconomic and Investment Newsletter

    SAN FRANSICO, CA / ACCESSWIRE / January 30, 2019 / Vista Partners ("Vista") has published January 2019's FREE Macroeconomic & Investment Monthly Newsletter, "Global Expansion Slows." ...

  • GlobeNewswire4 months ago

    Atossa Genetics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2019

    In 2018, we completed our transformation into a Phase 2 clinical-stage pharmaceutical company. Building on that momentum, our 2019 goals are a three-fold, laser-focused clinical program to continue the development of novel therapeutics and delivery methods to: 1) treat breast cancer, 2) reduce the risk of breast cancer, and 3) prevent/reduce gynecomastia. Throughout 2018, we advanced our Endoxifen programs into Phase 2 clinical studies for estrogen receptor positive (ER+) breast cancer and executed a research and development program of immunotherapies (such as Chimeric Antigen Receptor Therapy, or CAR-T) intended for targeted delivery via our proprietary microcatheters for the potential treatment of “triple negative” breast cancer (TNBC) and BRCA+ breast cancer.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Trending Tickers: BioTelemetry and Atossa Genetics

    NEW YORK, NY / ACCESSWIRE / January 10, 2019 / U.S. markets rose for the fourth consecutive session on Wednesday as minutes released from the Federal Reserve's meeting in December showed the Fed would ...

  • ACCESSWIRE4 months ago

    4 Healthcare Stocks Looking To Set January Highs

    CORAL GABLES, FL/ ACCESSWIRE / January 9, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Given that the world's population is consistently increasing, and resources are diminishing, access to healthcare is something crucial to the health and wellness of every living person, presenting a dire need for companies on a global scale. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare.

  • GlobeNewswire4 months ago

    Atossa Genetics Announces Successful Completion and Final Results from Male Phase 1 Study of Topical Endoxifen

    Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, reported final results from its Phase 1 dose-escalation study of its proprietary topical Endoxifen in male subjects. Atossa reported preliminary results from this study on September 13, 2018 and those results are now final. Safety: There were no clinically significant safety signals and no clinically significant adverse events in participants receiving topical Endoxifen.

  • GlobeNewswire5 months ago

    Detailed Research: Economic Perspectives on American Airlines Group, Sandstorm Gold, Kala Pharmaceuticals, Adecoagro S.A, Novagold Resources, and Atossa Genetics — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Dec. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE5 months ago

    "The Roller Coaster Ride Continues"

    SAN FRANCISCO, CA / ACCESSWIRE / December 19, 2018 / Vista Partners ("Vista") has published December's FREE Macroeconomic & Investment Monthly Newsletter, "The Roller Coaster Ride Continues." ...

  • GlobeNewswire5 months ago

    Edison issues outlook on Atossa Genetics (ATOS)

    LONDON, Dec. 07, 2018 -- Atossa Genetics’s (ATOS) endoxifen programs are advancing in their respective breast health programs. The firm recently reported positive safety data.

  • GlobeNewswire6 months ago

    Atossa Genetics Announces FDA Approval  of Endoxifen for “Expanded Access” as Preoperative Systemic Endocrine Therapy for a U.S. Breast Cancer Patient

    Steven C. Quay, Ph.D., MD, President and CEO commented, “A physician recently contacted Atossa and requested our proprietary oral Endoxifen for a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient awaiting surgery. In this setting, the recommended preoperative endocrine systemic therapy is typically an aromatase inhibitor and a drug for ovarian suppression.

  • ACCESSWIRE6 months ago

    ''A Spate of Factors'' Vista Partners November 2018 Macro Economic and Investment Newsletter

    SAN FRANCISCO, CA / ACCESSWIRE / November 21, 2018 / Vista Partners ("Vista") has published November's FREE Macroeconomic & Investment Monthly Newsletter, "A Spate of Factors." Vista's ...